AZ's Fasenra Gets Boost From Steroid-Sparing Data
Expansion Plans For Big-Selling Biologic
The POTENTE trial demonstrated Fasenra’s impact in eliminating or reducing oral corticosteroid use for severe asthma patients, which should help AstraZeneca as it takes on GlaxoSmithKline’s rival IL-5 inhibitor, Nucala.
You may also be interested in...
The UK’s Vectura plc is gaining value from its back catalog of novel compounds through licensing its pan-JAK inhibitor, VR588, to a US start-up, the venture capital-backed Kinaset Therapeutics.
The Swiss group has delivered on its promise to secure more deals in the nephrology space by bagging the rights in Europe, Australia and New Zealand to sparsentan, which is deep into a Phase III program for focal segmental glomerulosclerosis and IgA nephropathy.
Shares in Sweden's Calliditas have taken a tumble on the news that the US FDA has pushed back the action date for its immunoglobulin A nephropathy Nefecon. However, the company, and certain analysts, are less worried, believing the delay is just a blip.